South America Constipation Market is expected to grow at a high CAGR during the forecasting period (2022-2029).
South America Constipation Market Scop
By Disease Type, By Therapeutic ,By Distribution Channel, By Application, and By Region
Report Insights Covered
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region
Largest Market Share
Get A Free Sample Click Here
Constipation is the most common chronic gastrointestinal disorder in adults. It is more common in women, the elderly, and children. Specifically, constipation with no known cause affects females more often than males. As per DataM Intelligence, South America Constipation Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global South America Constipation Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. South America Constipation Market in the United States and Canada produces the utmost share. Whereas the European South America Constipation Market is projected to continue its presence globally during the period of 2022- 2029.
The South America constipation market is growing owing to several factors such as the rising geriatric population, treatment or new drugs development and rising prevalence of IBS-C, OIC, and chronic constipation.
Rising treatments and latest drugs in market and rising prevalence of IBS-C, OIC, and chronic constipation is expected to drive market growth.
In South American countries, the aging population is expected to accelerate significantly. Constipation is a chronic, multifunctional problem that is more prevalent in women and the elderly. Its incidence varies from 7.72% to 42.86% in individuals older than 70 years.
South America’s population aged 65 or over will triple to 18 percent by 2050. Between 2021 and 2050, Latin America and the Caribbean will see an increase in their share of the world’s older population from 8 percent in 2021 to 9 percent in 2050.
Rising living standards and better access to quality health care have increased Latin Americans' life expectancy to close to 75 years. Chileans and Costa Ricans can expect to live more than 80 years, slightly longer than United States residents.
According to a Brazil study, the prevalence of IC in the elderly in this study was 14.23%. The prevalence of IC and its associated factors is more frequently observed in females. The association with IC was found in the elderly with chronic diseases, cancer, opioid use, and lack of fluids influencing fecal cake strength.
Data from a national study on the increased prevalence of constipation in the elderly showed that IH's prevalence was greater in females, representing 89.2% of the analysed sample of constipated individuals, and in the elderly 80 years old or older, females constituted 67.6%.
Dependence on over-the-counter drugs is expected to hamper the market growth.
Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs is the main the factors hampering the growth of the market.
The South America constipation market provides in-depth analysis of the market based on various industry factors such as Porter’s Five Forces, Pipeline Analysis, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Product Innovation, Unmet Needs, Comparative Scenario.
Irritable bowel syndrome segment is expected to hold the largest market share in South America constipation market
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Symptoms of IBS include cramping, abdominal pain, bloating, gas, diarrhea, and constipation. Diagnosis of irritable bowel syndrome is made by tests such as blood tests, stool tests, endoscopic procedures, and external imaging procedures. In contrast, the treatment includes relieving the patient from the symptoms and improving the quality of life.
Increasing launches of various pipeline drugs mainly drive the irritable bowel syndrome with constipation (IBS-C) market for the treatment over the forecast period. The rising prevalence of gastrointestinal diseases and disorders, unhealthy diet, anxiety, and changing lifestyle in South America also drive the market's growth.
In Uruguay, according to a study, the overall prevalence of 10.9% (14.8% in women and 5.4% in men)—58% with IBS-C and 17% with IBS-D. In 72% of the cases, the age of onset was < 45 years.
A study from Venezuela reported an IBS prevalence of 16.8%, with 81.6% of those affected being women and 18.4% men. Studies on indigenous populations in Latin America revealed a high prevalence of IBS, which was similar to that in the rest of the population.
The major market players adopt various key strategies such as partnerships, collaborations, and product launches to gain a competitive advantage. For instance,
In September 2019, Ardelyx, Inc., a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that the U.S. Food and Drug Administration had approved IBSRELA (tenapanor), a 50 mg, a twice-daily oral pill for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to inhibit the sodium-hydrogen exchanger NHE3, resulting in increased bowel movements a decrease in abdominal pain for IBS-C patients.
Brazil region holds the largest market share in the South America constipation market
Constipation is a common problem with an incidence between 40% and 90% of patients treated with opioids and may appear after a single dose. The consequence of constipation over time is related to increased morbidity and mortality and worsening of patients' quality of life.
Growing awareness and rising incidence and prevalence of chronic idiopathic constipation - CIC are the major factors driving Brazil's constipation drugs market. Growth in demand for CIC drugs in South America, coupled with the huge gap of unmet needs in the region, is expected to serve as a significant opportunity in the constipation market during the forecast period.
Huge investments in research and development for the opioid-induced constipation market are the major opportunity for Brazil's market growth.
Side effects associated with laxatives and lack of proper treatment options are helping the market growth.
Due to the lack of immediate-release opioids for oxycodone and hydromorphone, escapes are empirically made with morphine in Brazil. However, the pharmacological association of agents acting on the same type of receptor is not recommended.
Non-medical use of opioids in Brazil may be more prevalent than previously recognized. Proper measurement and evaluation of opioid misuse across Brazil and other Latin American countries are critical to understanding and preventing opioid-related harms.
Some of the major players in the constipation market include Takeda Pharmaceutical Company Ltd, Abbott Laboratories, AstraZeneca, Sanofi, Bayer AG, Daewoong Pharmaceuticals, Bausch Health Companies Inc., Janssen Pharmaceutical, among others.
Manufacturers' large investments in developing therapeutic drugs for constipation are expected to fortify South America's market. These ardent efforts by the manufacturers of therapeutic drugs for constipation treatment have aided the constipation market's growth.
The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the sports medicine market globally. For instance,
In January 2019, Ironwood Pharmaceuticals Inc. and Allergan plc settled a patent dispute with Mylan NV over the generic maker's version of Linzess, a drug that treats irritable bowel syndrome constipation.
In April 2019, Takeda Pharmaceuticals U.S.A., Inc., (“Takeda”) announced that Motegrity™ (prucalopride), a once-daily, oral treatment option, is now commercially available by prescription for adults with chronic idiopathic constipation (CIC).
South America Constipation Market – Key Companies to Watch
Takeda Pharmaceutical Company Ltd.:
Overview: Takeda Pharmaceutical Co Ltd is a pharmaceutical company that is research based and develops, manufactures and markets pharmaceutical drugs. They provide products in various fields such as oncology, gastrointestinal, plasma-derived therapies, vaccines etc. Takeda was founded in 1789 and is headquartered in Tokyo, Japan.
Motegrity: It is a serotonin-4 receptor agonist used as medication for chronic idiopathic constipation. It is an oral treatment that is consumed once daily.
Key Developments: In October 2021, Takeda acquired Gamma Delta Therapeutics along with its programme on T cell immunotherapy.
The South America constipation market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
What is the Projected CAGR value of the South America Constipation Market?
South America Constipation Market is expected to grow at a CAGR of high during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the South America Constipation Market during 2022-2029.
Which is the fastest growing region in the South America Constipation Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period.
Get your free sample proposal with a single click!